Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of intranasal esketamine on cognitive functioning in healthy participants is assessed in this study. METHODS: computerized test battery assessed at 1 h predose and 40 min, 2, 4, and 6 h postdose. Secondary measures included the Mental Effort Scale, Karolinska Sleepiness Scale (KSS), and safety. RESULTS: Esketamine was associated with significant cognitive performance impairment at 40 min postdose for all five Cogstate® tests (Detection p = 0.0011, Identification p = 0.0006, One-Card Learning p = 0.0040, One Back p = 0.0017, and Groton Maze Learning Test p < 0.0001) versus placebo. In contrast, performance on these tests did not differ significantly between esketamine and placebo at 2, 4, or 6 h postdose. Secondary outcomes indicated a significant, transient increase from baseline under esketamine versus placebo at 40 min postdose on the Mental Effort Scale and at 40 min and 2 h postdose on KSS (p < 0.0001 for both); however, no significant difference was observed on these outcomes between esketamine and placebo at later timepoints. The most commonly reported adverse events were dizziness (67%), nausea (37.5%), disturbance in attention (29.2%), and fatigue (29.2%); the majority were considered mild in severity. CONCLUSIONS: Esketamine was associated with cognitive performance decline, and greater effort was required to complete the test battery versus placebo at 40 min postdose, which returned to placebo-comparable levels by 2 h postdose. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02094378.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 3×
“…showing improved performance at 10 h postdose merits further investigation, particularly in light of preclinical evidence in rodents that a single administration of ketamine alters synaptic plasticity in the hippocampus and medial prefrontal cortex (Kavalali and Monteggia 2012; Duman et al. 2016).”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 3×
“Intravenous ketamine has shown impairing effects on cognitive performance parameters that typically peak following administration and resolve within a few minutes to up to 2 h after drug discontinuation (Mathew et al. 2010; Murrough et al. 2013a, b; Zarate et al. 2006).”
BackgroundInfluentialMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 3×
“Intravenous ketamine has shown impairing effects on cognitive performance parameters that typically peak following administration and resolve within a few minutes to up to 2 h after drug discontinuation (Mathew et al. 2010; Murrough et al. 2013a, b; Zarate et al. 2006).”
BackgroundInfluentialDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Self-citationSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Maruff, P., Thomas, E., Cysique, L., Brew, B., Collie, A., Snyder, P., & Pietrzak, R. H. (2009) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acp010 · Cited by 635
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Research works printed but not linked: 24
- Andrade C (2015) Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. J Clin Psychiatry 76:628–631 · DOI · Paper page
- Bitter C (2011) Transmucosal nasal drug delivery: pharmacokinetics and pharmacodynamics of nasally applied esketamine. Dissertation, University of Basel
- Collie A, Maruff P, McStephen M, Darby D (2003) Psychometric issues associated with computerised neuropsychological assessment of concussed athletes. Br J Sports Med 37(6):556–559. https://doi.org/10.1136/bjsm.37.6.556 · DOI
- Daly E, Singh J, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC (2017) Efficacy and safety of intranasal esketamine in treatment-resistant depression: results of a double-blind, doubly-randomized, placebo-controlled study. Am J Psychiatry. In press
- Diamond PR, Farmery AD, Atkinson S, Haldar J, Williams N, Cowen PJ, Geddes JR, McShane R (2014) Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 28(6):536–544. https://doi.org/10.1177/0269881114527361 · DOI · Paper page
- Diaz JH (1997) Intranasal ketamine preinduction of paediatric outpatients. Paediatr Anaesth 7(4):273–278. https://doi.org/10.1046/j.1460-9592.1997.d01-93.x · DOI
- Himmelseher S, Pfenninger E (1998) The clinical use of S-(+)-ketamine--a determination of its place. Anasthesiol Intensivmed Notfallmed Schmerzther 33(12):764–770. https://doi.org/10.1055/s-2007-994851 · DOI
- Louon A, Reddy VG (1994) Nasal midazolam and ketamine for paediatric sedation during computerised tomography. Acta Anaesthesiol Scand 38(3):259–261. https://doi.org/10.1111/j.1399-6576.1994.tb03885.x · DOI
- Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr (2009) Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123(2):143–150. https://doi.org/10.1016/j.pharmthera.2009.02.010 · DOI · Paper page
- Maruff P, Falleti MG, Collie A, Darby D, McStephen M (2005) Fatigue-related impairment in the speed, accuracy and variability of psychomotor performance: comparison with blood alcohol levels. J Sleep Res 14(1):21–27. https://doi.org/10.1111/j.1365-2869.2004.00438.x · DOI
- Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13(1):71–82. https://doi.org/10.1017/S1461145709000169 · DOI · Paper page
- Morgan CJ, Curran HV (2006) Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology 188(4):408–424. https://doi.org/10.1007/s00213-006-0572-3 · DOI · Paper page
- Morgan CJ, Muetzelfeldt L, Curran HV (2009) Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104(1):77–87. https://doi.org/10.1111/j.1360-0443.2008.02394.x · DOI · Paper page
- Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE (2014) Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 231(3):481–488. https://doi.org/10.1007/s00213-013-3255-x · DOI · Paper page
- Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, Kegeles LS, Talbot PS, Huang Y, Hwang DR, Khenissi L, Cooper TB, Laruelle M, Abi-Dargham A (2005) Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162(12):2352–2359. https://doi.org/10.1176/appi.ajp.162.12.2352 · DOI · Paper page
- Olver JS, Ignatiadis S, Maruff P, Burrows GD, Norman TR (2008) Quetiapine augmentation in depressed patients with partial response to antidepressants. Hum Psychopharmacol 23(8):653–660. https://doi.org/10.1002/hup.970 · DOI
- Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ (2009) A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 31(7):848–859. https://doi.org/10.1080/13803390802592458 · DOI · Paper page
- Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80(6):424–431. https://doi.org/10.1016/j.biopsych.2015.10.018 · DOI · Paper page
- Snyder PJ, Werth J, Giordani B, Caveney AF, Feltner D, Maruff P (2005) A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. Hum Psychopharmacol 20(4):263–273. https://doi.org/10.1002/hup.692 · DOI · Paper page
- Verster JC, van de Loo AJ, Roth T (2015) Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. Eur J Pharmacol 753:252–256. https://doi.org/10.1016/j.ejphar.2014.10.032 · DOI
- Weber F, Wulf H, El Saeidi G (2003) Premedication with nasal s-ketamine and midazolam provides good conditions for induction of anesthesia in preschool children. Can J Anaesth 50(5):470–475. https://doi.org/10.1007/BF03021058 · DOI
- Weksler N, Ovadia L, Muati G, Stav A (1993) Nasal ketamine for paediatric premedication. Can J Anaesth 40(2):119–121. https://doi.org/10.1007/BF03011307 · DOI
- Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T (2003) Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 24(1):37–43. https://doi.org/10.1002/bdd.336 · DOI · Paper page
- Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T, Shiina A, Hashimoto T, Kanahara N, Hasegawa T, Enohara M (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7(8):e42676. https://doi.org/10.1371/journal.pone.0042676 · DOI · Paper page
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Also, 1-year exposure to intranasal esketamine in adults with TRD has not been reported to result in impairment in cognitive function (91).”
BackgroundHashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“The intranasal single injection of (S)-ketamine produced a decline of cognitive performance in healthy control subjects 40 min after a single dose (84 mg).(61) There was no difference in the driving performance in healthy control subjects at 8 h after the intranasal single injection of (S)-ketamine (84 mg).”
BackgroundMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Esketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Metadata
- Authors
- Morrison, R. L., Fedgchin, M., Singh, J., Van Gerven, J., Zuiker, R., Lim, K. S., van der Ark, P., Wajs, E., Xi, L., Zannikos, P., & Drevets, W. C.
- Venue
- Psychopharmacology
- Published
- 2018-02-01
- Volume
- 235
- Issue
- 4
- Pages
- 1107-1119
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2793977798
- Cited by
- 72
- References
- 16
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- Funders
- Janssen Research and Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1007/s00213-018-4828-5
- The paper
- Morrison, R. L., Fedgchin, M., Singh, J., Van Gerven, J., Zuiker, R., Lim, K. S., van der Ark, P., Wajs, E., Xi, L., Zannikos, P., & Drevets, W. C. (2018). Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study. Psychopharmacology. https://doi.org/10.1007/s00213-018-4828-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.